ɬÀï·¬

Journal News

Antibiotic sensor directly binds drug in resistant bacteria

Emily Ulrich
Oct. 8, 2025

Vancomycin-resistant enterococci bacteria, or VRE, cause serious hospital-acquired infections, prompting scientists to search for new ways to target these hard-to-treat pathogens. VRE detect vancomycin through a transmembrane histidine kinase, called VanS, which phosphorylates the transcription factor VanR. Once phosphorylated, VanR triggers the production of enzymes that shield the bacterial cell wall from vancomycin’s effects. Ten genetic variants of this system exist, and disrupting it could restore vancomycin’s effectiveness. However, scientists do not understand how VanS senses vancomycin. Lina Maciunas, Photis Rotsides and a team at Drexel University College of Medicine tackled this question in their recent Journal of Biological Chemistry .

Pink colonies on an agar plate indicate growth of vancomycin-resistant enterococci.

The team developed an assay to study type-B VanS in nanodiscs, which mimic the cell membrane environment for purified membrane proteins. VanS performs three functions: autophosphorylation, transferring the phosphate group to VanR and dephosphorylating VanR. Testing these functions with vancomycin, the authors found increased autophosphorylation and slightly decreased dephosphorylation, consistent with the antibiotic activating the resistance system.

They then used a modified vancomycin photoaffinity probe and detected direct binding of the VanS sensor domain in the nanodisc, as assessed by mass spectrometry. Isothermal titration calorimetry confirmed that this interaction is specific for vancomycin since VanS did not bind a similar antibiotic.

Future work will explore how other VanS variants interact with vancomycin. Detailed insight into this interaction could guide inhibitor design to block antibiotic resistance in severe infections.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Protein modifications drive lung cancer resistance
Journal News

Protein modifications drive lung cancer resistance

Nov. 6, 2025

New assay enriches protein modifications in a single process, enabling detection of key changes in drug-resistant lung cancer cells that may guide future therapies.

How antigen-processing proteins shape immunity
Journal News

How antigen-processing proteins shape immunity

Nov. 6, 2025

Researchers show how components of the antigen processing machinery shape the immunopeptidome, offering insights into immune regulation and cancer biology.

New chemical strategy boosts accuracy in proteomics
Journal News

New chemical strategy boosts accuracy in proteomics

Nov. 6, 2025

Researchers develop a methylamine-based method that nearly eliminates peptide overlabeling in proteomics, improving accuracy in protein identification and quantitation.

Understanding the roles of extracellular matrix and vesicles in valvular disease
Profile

Understanding the roles of extracellular matrix and vesicles in valvular disease

Oct. 30, 2025

MOSAIC scholar Cassandra Clift uses mass spectrometry and multiomics to study cardiovascular calcification and collagen dysregulation, bridging her background in bioengineering and biology to investigate extracellular vesicles and heart disease.

Lipid profiles reveal sex differences in type 2 diabetes
Journal News

Lipid profiles reveal sex differences in type 2 diabetes

Oct. 29, 2025

Researchers explored the lipid profiles of individuals with type 2 diabetes and identified potentially useful lipid biomarkers for this condition.

Serum lipids may predict early diabetes risk
Journal News

Serum lipids may predict early diabetes risk

Oct. 29, 2025

Researchers found that levels of two key fatty acids may predict worsening tolerance for glucose, independent of body fat and insulin levels. In turn, these fatty acids may serve as early T2D biomarkers.